erlotinib hydrochloride has been researched along with tyrphostin ag 1024 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tyrphostin ag 1024) | Trials (tyrphostin ag 1024) | Recent Studies (post-2010) (tyrphostin ag 1024) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 89 | 0 | 52 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | tyrphostin ag 1024 (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
1 other study(ies) available for erlotinib hydrochloride and tyrphostin ag 1024
| Article | Year |
|---|---|
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cetuximab; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Quinazolines; Tyrphostins | 2005 |